Here are the 10-K annual reports from MOSAIC IMMUNOENGINEERING (CPMV) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CPMV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPMV filings page.
Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company aiming to build an immuno-oncology pipeline but currently has no active product candidates. The company focuses on licensing or acquiring cancer immunotherapies rather than advancing an existing in-house portfolio.
As of December 31, 2025, Mosaic reported cash of $3,622, current liabilities of $6,030,055 and an accumulated deficit of $9,526,166. Management states there is substantial doubt about its ability to continue as a going concern because existing resources are insufficient to fund current obligations or planned operations for the next twelve months.
Mosaic entered a binding term sheet with Oncotelic Therapeutics in April 2024 to acquire clinical-stage necroptosis cancer therapies and AI technology in exchange for equity valued at $15.0 million, plus up to an additional $15.0 million in milestone shares, but the term sheet expired on June 30, 2025 and no definitive agreement has been finalized. The company is highly dependent on raising additional capital, including convertible notes, and warns that failure to secure funding could force it to cease operations.